Developing new treatments for muscular dystrophy using RNA technology
Official title: (Project 2) Development of U7snRNA Vectors for Dystrophinopathy
Funded at Research Inst Nationwide Children's Hosp · NIH-10992527 · Data updated 2026-11-12
This study is exploring new ways to help people with muscular dystrophies, like Duchenne and Becker muscular dystrophy, by using special tools to improve the production of a protein called dystrophin, which is important for muscle health, and it aims to create personalized treatments based on each person's unique genetic makeup.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $351,482 |
| NIH project number | 1P50HD117373-01A1 |
| Project ID | NIH-10992527 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy or Becker muscular dystrophy, particularly those with specific genetic mutations that can be targeted by the developed therapies.
✕Less likely to help
Patients with muscular dystrophies that do not have mutations amenable to the proposed RNA splicing alterations may not benefit from this research.
What this research studies
This research focuses on creating innovative vectors that can alter RNA splicing to improve the production of dystrophin protein in patients with muscular dystrophies, particularly Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). By utilizing a personalized medicine approach, the study aims to tailor therapies based on individual genetic mutations, potentially allowing for the expression of full-length dystrophin in patients with specific mutations. The methodology involves using adeno-associated virus (AAV) vectors to deliver these therapeutic agents effectively to muscle cells. The goal is to enhance the efficacy of existing treatments and provide better outcomes for patients with these conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for muscular dystrophy, improving muscle function and quality of life for affected patients.
How similar studies have gone: Previous research has shown promise in using RNA-based therapies for muscular dystrophies, indicating that this approach has the potential for success.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Flanigan, Kevin M — Research Inst Nationwide Children's Hosp
- Study coordinator: Flanigan, Kevin M
Related research
Other NIH-funded projects on the same topics.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Atomoxetine for MC4R obesity in children
A trial tests whether an ADHD drug, atomoxetine, can help children with a genetic form of obesity caused by MC4R mutations.
-
Collaborative Pediatric Critical Care Network: Clinical Site
A nationwide network study aims to tailor sepsis treatment for children with organ failure based on each child’s immune profile.
-
How dietary fats may make platelets overactive in obesity
A study in adults with obesity will explore how saturated fats in the diet change platelet membranes and make platelets act more likely to clump and react, which could affect heart and blood vessel health.
-
Understanding how environment and microbiome affect health in children with sickle cell disease
A research project will explore how environmental exposures shape immune responses and airway microbiomes in children with sickle cell disease and how these factors relate to health outcomes.
-
Pediatric cancer biospecimen bank and research collaboration fund
This grant supports the Children’s Oncology Group to collect, bank, and share tumor and other biospecimens from children and adolescents with cancer for research.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.